Arthritis Rheumatoid
📧 Sign up to get email alerts when something new happens for Arthritis Rheumatoid.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2021-03-03Clinical Trial Update: Low Dose Naltrexone for Chronic Pain From Arthritis [Phase 2]
Phase 2 clinical trial of low-dose naltrexone for chronic pain from arthritis has completed; results posted in 2021.
-
EMA withdrawal · 2021-01-29EMA Withdrawn: Halimatoz (adalimumab) — Sandoz GmbH
The EMA withdrew Halimatoz (adalimumab) supplied by Sandoz GmbH from the market.
-
EMA withdrawal · 2020-06-24EMA Application withdrawn: Rituximab Mabion (rituximab) — Mabion Spolka Akcyjna
The EMA application for Rituximab Mabion (rituximab) by Mabion Spolka Akcyjna has been withdrawn.
-
EMA withdrawal · 2020-03-25EMA Withdrawn: Kromeya (adalimumab) — Fresenius Kabi Deutschland GmbH
EMA has withdrawn Kromeya (adalimumab) from Fresenius Kabi Deutschland GmbH, effective 2019, affecting multiple inflammatory diseases.
-
CLINICAL_TRIALS trial_result · 2018-12-14Clinical Trial Update: Clinical Study to Evaluate the Efficacy of Anakinra in Patients With Rheumatoid Arthritis and Diabetes [Phase 4]
A Phase 4 trial evaluating anakinra for efficacy in patients with rheumatoid arthritis and type 2 diabetes has been terminated.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2011-05-19Clinical Trial Update: APART Advanced Profiling of Anti-Rheumatic Therapies [Phase 4]
Phase 4 clinical trial update for anti-rheumatic therapies (APART study) has been completed.
-
CLINICAL_TRIALS trial_result · 2010-06-11Clinical Trial Update: Study Of Celecoxib Or Diclofenac And Omeprazole For Gastrointestinal (GI) Safety In High GI Risk Patients With Arthritis [Phase 4]
Phase 4 study comparing celecoxib or diclofenac with omeprazole for GI safety in high GI risk arthritis patients, completed with posted resu…